Kiadis draws €20 million from bridge loan with Sanofi
14 Janeiro 2021 - 3:00AM
Kiadis draws €20 million from bridge loan with Sanofi
This is a press release by Kiadis Pharma N.V.
pursuant to Section 17 paragraph 1 of the European Market Abuse
Regulation (596/2014) and in connection with the intended public
offer by Sanofi for all the issued and outstanding ordinary shares
in the capital of Kiadis Pharma N.V. (the "Offer"). This
announcement does not constitute an offer, or any solicitation of
any offer, to buy or subscribe for any securities. Any offer will
be made only by means of an offer memorandum approved by the Dutch
Authority for the Financial Markets (Autoriteit Financiële Markten)
and recognized by the Belgian Authority for the Financial Markets
(Autoriteit voor Financiële Diensten en Markten). This announcement
is not for release, publication or distribution, in whole or in
part, in or into, directly or indirectly, the United States, Canada
and Japan or in any other jurisdiction in which such release,
publication or distribution would be unlawful.
Kiadis draws €20 million from bridge loan
with Sanofi
Amsterdam, The Netherlands, January 14,
2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)
(Euronext Amsterdam and Brussels: KDS) today
announces that the Company has drawn €20 million from the Company’s
bridge loan with Sanofi (the “Bridge Loan”) to
bridge Kiadis’ capital needs through the closing of the acquisition
by Sanofi.
Agreement on its principal terms and the
intention to enter into the Bridge Loan were announced on November
2, 2020 and the Bridge Loan has been entered into on January 13,
2021. The Bridge Loan makes available a total of €27.7 million of
capital to be borrowed. Further information on the Bridge Loan will
be included in the offer memorandum, which is expected to be
published in Q1 2021.
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V. (“Kiadis” of de
“Vennootschap”) (Euronext Amsterdam en Brussel:
KDS) maakt vandaag bekend dat de Vennootschap EUR 20
miljoen heeft getrokken onder het overbruggingskrediet van de
Vennootschap bij Sanofi (het
“Overbruggingskrediet”) om zijn kapitaalbehoeften
te overbruggen tot de afronding van de overname door Sanofi.
Dat overeenstemming was bereikt over de
hoofdvoorwaarden en de intentie het Overbruggingskrediet te tekenen
was reeds aangekondigd op 2 november 2020, en ondertekening van het
Overbruggingskrediet vond plaats op 13 januari 2021. Het
Overbruggingskrediet maakt een totaalbedrag van EUR 27.7 miljoen
aan leningen beschikbaar. Meer informatie over het
Overbruggingskrediet zal worden opgenomen in het biedingsbericht,
dat naar verwachting in het eerste kwartaal van 2021 zal worden
gepubliceerd.
Dit is een samenvatting van het
Engelstalige persbericht. Bij eventuele verschillen is de tekst van
het Engelstalige persbericht altijd leidend.
For more information:
Kiadis: Maryann
Cimino, Director, Investor Relations & Corporate Affairs Tel:
+1 (617) 710 7305 m.cimino@kiadis.com |
Kiadis Media Relations
ContactsLifeSpring Life Sciences
Communication: Leon Melens (Amsterdam) Tel: +31 538 16 427
lmelens@lifespring.nlOptimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
|
|
About Kiadis
Founded in 1997, Kiadis is committed to
developing innovative cell-based medicines for patients with
life-threatening diseases. With headquarters in Amsterdam, The
Netherlands, and offices and activities across the United States,
Kiadis is reimagining medicine by leveraging the natural strengths
of humanity and our collective immune system to source the best
cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.Kiadis.com.
Kiadis Forward-Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis’ or, as
appropriate, Kiadis’ officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis expressly disclaims any obligation or
undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.